MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145724 | Name: SMW-139

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SMW-139 is a small molecule compound that has been studied primarily for its potential as a therapeutic agent in the context of cancer research. It is known to exhibit anticancer properties, particularly in terms of targeting specific biological pathways involved in tumor growth and progression. SMW-139 has been observed to inhibit cell proliferation in various cancer cell lines, which suggests that it may interfere with critical mechanisms that allow tumors to grow unchecked.

Chemical Structure

SMW-139
SMW-139
CAS#2133010-38-3

Theoretical Analysis

MedKoo Cat#: 145724

Name: SMW-139

CAS#: 2133010-38-3

Chemical Formula: C19H21ClF3NO2

Exact Mass: 387.1200

Molecular Weight: 387.83

Elemental Analysis: C, 58.84; H, 5.46; Cl, 9.14; F, 14.70; N, 3.61; O, 8.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SMW-139; SMW139; SMW 139;
IUPAC/Chemical Name
2-chloro-5-methoxy-N-((3,5,7-trifluoroadamantan-1-yl)methyl)benzamide
InChi Key
DWSQAAMUNCFYTG-UHFFFAOYSA-N
InChi Code
1S/C19H21ClF3NO2/c1-26-12-2-3-14(20)13(4-12)15(25)24-11-16-5-17(21)8-18(22,6-16)10-19(23,7-16)9-17/h2-4H,5-11H2,1H3,(H,24,25)
SMILES Code
COC1=CC=C(Cl)C(=C1)C(=O)NCC23CC4(F)CC(F)(CC(F)(C4)C2)C3
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 387.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Brumberg J, Aarnio R, Forsberg A, Marjamäki P, Kerstens V, Moein MM, Nag S, Wahlroos S, Kassiou M, Windhorst AD, Halldin C, Haaparanta-Solin M, Fazio P, Oikonen V, Rinne JO, Varrone A. Quantification of the purinergic P2X7 receptor with [11C]SMW139 improves through correction for brain- penetrating radiometabolites. J Cereb Blood Flow Metab. 2023 Feb;43(2):258-268. doi: 10.1177/0271678X221126830. Epub 2022 Sep 26. PMID: 36163685; PMCID: PMC9903223. 2: Hagens MHJ, Golla SSV, Janssen B, Vugts DJ, Beaino W, Windhorst AD, O'Brien- Brown J, Kassiou M, Schuit RC, Schwarte LA, de Vries HE, Killestein J, Barkhof F, van Berckel BNM, Lammertsma AA. The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):379-389. doi: 10.1007/s00259-019-04550-x. Epub 2019 Nov 8. PMID: 31705174; PMCID: PMC6974509. 3: Beaino W, Janssen B, Kooijman E, Vos R, Schuit RC, O'Brien-Brown J, Kassiou M, van Het Hof B, Vugts DJ, de Vries HE, Windhorst AD. PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139. J Neuroinflammation. 2020 Oct 14;17(1):300. doi: 10.1186/s12974-020-01962-7. PMID: 33054803; PMCID: PMC7556947. 4: Aarnio R, Alzghool OM, Wahlroos S, O'Brien-Brown J, Kassiou M, Solin O, Rinne JO, Forsback S, Haaparanta-Solin M. Novel plasma protein binding analysis method for a PET tracer and its radiometabolites: A case study with [11C]SMW139 to explain the high uptake of radiometabolites in mouse brain. J Pharm Biomed Anal. 2022 Sep 20;219:114860. doi: 10.1016/j.jpba.2022.114860. Epub 2022 May 28. PMID: 35738120. 5: Moein MM, Tóth M, Tari L, Varrone A, Abdel-Rehim M, Halldin C. New approach in radiometabolite analysis of positron emission tomography (PET) radioligands; lead-shielded microextraction by packed sorbent as a tool for in vivo radiometabolite analysis of [11C]SMW139 in rat plasma. Talanta. 2020 Feb 1;208:120449. doi: 10.1016/j.talanta.2019.120449. Epub 2019 Oct 5. PMID: 31816716. 6: Alzghool OM, Aarnio R, Helin JS, Wahlroos S, Keller T, Matilainen M, Solis J, Danon JJ, Kassiou M, Snellman A, Solin O, Rinne JO, Haaparanta-Solin M. Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA. EJNMMI Res. 2024 Mar 6;14(1):25. doi: 10.1186/s13550-024-01085-7. Erratum in: EJNMMI Res. 2024 May 3;14(1):44. doi: 10.1186/s13550-024-01103-8. PMID: 38446249; PMCID: PMC10917722. 7: Janssen B, Vugts DJ, Wilkinson SM, Ory D, Chalon S, Hoozemans JJM, Schuit RC, Beaino W, Kooijman EJM, van den Hoek J, Chishty M, Doméné A, Van der Perren A, Villa A, Maggi A, Molenaar GT, Funke U, Shevchenko RV, Baekelandt V, Bormans G, Lammertsma AA, Kassiou M, Windhorst AD. Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. Sci Rep. 2018 Apr 26;8(1):6580. doi: 10.1038/s41598-018-24814-0. PMID: 29700413; PMCID: PMC5920098. 8: Lehto J, Aarnio R, Tuisku J, Sucksdorff M, Koivumäki EM, Nylund M, Helin S, Rajander J, Danon J, Gilchrist J, Kassiou M, Oikonen V, Airas L. P2X 7-receptor binding in new-onset and secondary progressive MS - a [11C]SMW139 PET study. EJNMMI Res. 2024 Dec 5;14(1):123. doi: 10.1186/s13550-024-01186-3. PMID: 39636350; PMCID: PMC11621262. 9: Alzghool OM, Aarnio R, Helin JS, Wahlroos S, Keller T, Matilainen M, Solis J, Danon JJ, Kassiou M, Snellman A, Solin O, Rinne JO, Haaparanta-Solin M. Correction: Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA. EJNMMI Res. 2024 May 3;14(1):44. doi: 10.1186/s13550-024-01103-8. Erratum for: EJNMMI Res. 2024 Mar 6;14(1):25. doi: 10.1186/s13550-024-01085-7. PMID: 38700617; PMCID: PMC11068707.